Literature DB >> 25956664

Intracranial involvement by multiple myeloma.

A Lasocki1, S Gangatharan2, F Gaillard3, S J Harrison4.   

Abstract

Intracranial involvement is a rare complication of multiple myeloma. It results either from direct extra-osseous spread from adjacent skeletal plasmacytomas or extra-medullary disease via haematogenous dissemination. The imaging appearances are non-specific, and dural, leptomeningeal, and parenchymal involvement can all occur. The purpose of this review is to illustrate the various neuroimaging appearances of this rare entity, focusing on MRI.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2015        PMID： 25956664     DOI： 10.1016/j.crad.2015.03.014

Source DB:  PubMed          Journal:  Clin Radiol        ISSN： 0009-9260            Impact factor:   2.350


  5 in total

Review 1.  Multiple myeloma of the spine.

Authors:  Arian Lasocki; Frank Gaillard; Simon J Harrison
Journal:  Neuroradiol J       Date:  2017-04-20

2.  Intracranial Involvement in Multiple Myeloma Presenting as a Cranial Nerve Palsy.

Authors:  Eilis Fitzgerald; Patrick Kiely; Hilary O Leary
Journal:  J Hematol (Brossard)       Date:  2019-03-30

3.  Intracranial plasmacytoma arising from dura mater secondary to multiple myeloma and presenting with sudden lethal intracerebral hemorrhage: A case report and literature review.

Authors:  Koki Onodera; Kota Kurisu; Seiji Takebayashi; Juro Sakurai; Tohru Kobayashi; Rina Kobayashi; Shuho Goto; Katsumi Takizawa
Journal:  Surg Neurol Int       Date:  2021-02-17

4.  Successful eradication of leptomeningeal plasma cell disease.

Authors:  Øyvind Bruserud; Bent-Are Hansen; Nils Vetti; Silje Johansen; Håkon Reikvam
Journal:  Oxf Med Case Reports       Date:  2018-07-03

Review 5.  Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging.

Authors:  Karla M Treitl; Jens Ricke; Andrea Baur-Melnyk
Journal:  Skeletal Radiol       Date:  2021-05-24       Impact factor: 2.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.